Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope.
about
Plant Viruses as Nanoparticle-Based Vaccines and AdjuvantsVirus-Based Nanoparticles as Versatile NanomachinesDual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virusAn induced hypersensitive-like response limits expression of foreign peptides via a recombinant TMV-based vector in a susceptible tobacco.Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.Virus-neutralizing monoclonal antibody expressed in milk of transgenic mice provides full protection against virus-induced encephalitis.Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope.Use of viral vectors for vaccine production in plants.Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.Feasibility of Cowpea chlorotic mottle virus-like particles as scaffold for epitope presentations.Immune response to a potyvirus with exposed amino groups available for chemical conjugation.Transgenic plants in the biopharmaceutical market.Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens.Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.Plant-derived virus-like particles as vaccinesThe Impact of Aspect Ratio on the Biodistribution and Tumor Homing of Rigid Soft-Matter NanorodsGenetically engineered Tobacco mosaic virus as nanoparticle vaccines.Manipulation of the bluetongue virus tubules for immunogen delivery.Recent progress in the development of plant derived vaccines.Design of virus-based nanomaterials for medicine, biotechnology, and energy.Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in miceViral nanoparticles and virus-like particles: platforms for contemporary vaccine design.Exploiting plant virus-derived components to achieve in planta expression and for templates for synthetic biology applications.Enhancing Antibody Response against Small Molecular Hapten with Tobacco Mosaic Virus as a Polyvalent Carrier.Synthetic plant virology for nanobiotechnology and nanomedicineTobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agentsIdentification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.In planta production of flock house virus transencapsidated RNA and its potential use as a vaccine.Ecdysone agonist-inducible expression of a coat protein gene from tobacco mosaic virus confers viral resistance in transgenic Arabidopsis.High-yield expression of a viral peptide vaccine in transgenic plants.A plant virus vector for systemic expression of foreign genes in cereals.Plant-Based Vaccines: Production and Challenges
P2860
Q26782569-8A4BE6BF-1B46-4982-9ED2-90EC7D3469FAQ28068538-1FF9C62D-8AF9-4846-9E33-C0214FB720ADQ30587267-2FDFBCB0-CC8C-4BF7-9D1B-C470DECB457FQ33760638-D31C7FB5-FEE8-489B-B9AD-4BEFB2DD9FB8Q33854138-46027241-237F-4A9C-AC60-928FC9934362Q33865777-1B95945D-7604-458B-82D0-95022C576A5AQ34348810-13A2AA32-12BF-4117-AD1C-FE5C04B07A52Q34416460-A2851221-037B-438A-A123-A512D61586B6Q34438091-91F6FBB1-A444-41FF-8BD6-0C389DF95BEDQ35756792-0CBB969B-6829-48B7-89C1-4E102A29AFC0Q35984242-B6FBD80D-D285-4142-87FF-D54C8FAECA18Q36066053-447002BF-C98B-4487-A7EB-2FDE4143A359Q36186712-CEE22751-FB40-4610-9127-737839040CCFQ36602721-5E804AC5-A311-485B-B602-8EEC3699D7F4Q36888029-14296233-BBC9-48A2-9821-348C23C1A617Q37068238-096DBFCC-0BC1-4309-9D81-565A615D4EDEQ37077649-072D811F-E851-4F11-BFCB-90FB23CB826EQ37174137-1854792F-AA50-4694-A939-C890458DD4E6Q37290098-B72B9CD9-0616-4E75-9DD8-730E3B059D70Q37346447-EA1E45C6-AD3C-4927-8932-BCD6002DEE6AQ37531135-946D53F4-3A10-483B-B5B3-E5645FA843BAQ37792984-1AEAAD03-9484-4094-BD41-03E71AFA23C3Q38085709-8722022C-C4F9-435E-B15A-6D003EB88F0EQ38882114-DAC62BC1-B98A-4E8E-885D-27A85DBD522BQ39081725-8FB2DAE3-9E0E-470F-9B54-3A1609FFB4C2Q39804161-CA481048-4898-499B-8891-32F377760480Q40471278-42D2AD8C-9C38-4C9A-9186-25E8A1AD2F63Q41644443-C23DFB35-4B58-4020-89F1-E5FAE8EBB5F8Q44734050-96A1EED1-C009-4242-B7FC-0CF32935777CQ44911177-72F1FD77-D2C9-4341-8EEA-49B8B6A7201DQ45740794-8A4573E5-AAB7-40FA-ABE9-11E7DC88E510Q59125274-5FE4AC89-CEA2-457B-8006-425271B1537D
P2860
Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Protective immunity against mu ...... s that carries an MHV epitope.
@ast
Protective immunity against mu ...... s that carries an MHV epitope.
@en
type
label
Protective immunity against mu ...... s that carries an MHV epitope.
@ast
Protective immunity against mu ...... s that carries an MHV epitope.
@en
prefLabel
Protective immunity against mu ...... s that carries an MHV epitope.
@ast
Protective immunity against mu ...... s that carries an MHV epitope.
@en
P2093
P2860
P356
P1476
Protective immunity against mu ...... s that carries an MHV epitope.
@en
P2093
A D Paoletti
G A Lettieri
J H Fitchen
M Bendahmane
M J Buchmeier
R N Beachy
P2860
P304
P356
10.1073/PNAS.96.14.7774
P407
P577
1999-07-01T00:00:00Z